Multi-Cancer Early Detection (MCED) & Companion Diagnostics Market
完整報告名稱與涵蓋範圍
Multi-Cancer Early Detection (MCED) & Companion Diagnostics Market Size, Share & Trends Analysis Report, By Test Type (Multi-Cancer Early Detection Screening Tests, Single-Cancer Blood-Based Screening Tests, Companion and Complementary Diagnostics (Tissue and Liquid), Tumor Profiling Panels Supporting Therapy Selection), By Technology (Cell-Free DNA Methylation and Fragmentomics, Next-Generation Sequencing Panels, PCR, Immunohistochemistry and In Situ Hybridization, Proteomic and Multi-Omic Signatures), By End User (Hospitals and Cancer Centers, Reference and Specialty Laboratories, Primary Care, Employers and Screening Programs, Pharmaceutical and Biotechnology Companies), By Region, and Segment Forecasts, 2026-2035
報告摘要
The multi-cancer early detection and companion diagnostics market covers blood-based tests that screen asymptomatic individuals for multiple or single cancers, and companion and complementary diagnostics and tumor profiling panels that determine eligibility for targeted and immuno-oncology therapies, spanning methylation and fragmentomic cell-free DNA assays, sequencing panels, PCR, immunohistochemistry and multi-omic signatures. Together these represent the two ends of the cancer molecular diagnostics continuum, and the study quantifies each separately while analysing shared technology and laboratory infrastructure. General liquid biopsy monitoring applications are covered in a separate InsightAce study.
Multi-cancer early detection has moved from research to large prospective trials and early commercial availability, with regulatory submissions and national screening pilots that will determine whether blood tests can add cancers without established screening programs to routine care; reimbursement and evidence on mortality benefit remain the decisive variables. Companion diagnostics continue to expand with every biomarker-defined drug approval, increasingly in liquid formats and as multi-gene panels that consolidate testing, and pharmaceutical companies co-develop assays to accelerate patient identification. Regulatory frameworks for laboratory developed tests, in vitro diagnostic regulation in Europe and sequencing cost declines shape both segments.
North America leads on commercialisation and reimbursement, with the United Kingdom, Europe, Japan and China running screening evaluations and expanding companion diagnostic use. Competition involves early detection specialists, sequencing and diagnostic platform leaders, tumor profiling laboratories and Asian genomic testing companies.
The InsightAce study supplies US$ forecasts for all test type, technology and end user and regional segments over 2026-2035, segment-level trend analysis, competitive landscape assessment and profiling of the leading companies.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Multi-Cancer Early Detection (MCED) & Companion Diagnostics Market Snapshot
Chapter 4. Global Multi-Cancer Early Detection (MCED) & Companion Diagnostics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Test Type Estimates & Trend Analysis
5.1. Test Type & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Test Type:
5.2.1. Multi-Cancer Early Detection Screening Tests
5.2.2. Single-Cancer Blood-Based Screening Tests
5.2.3. Companion and Complementary Diagnostics (Tissue and Liquid)
5.2.4. Tumor Profiling Panels Supporting Therapy Selection
Chapter 6. Market Segmentation 2: By Technology Estimates & Trend Analysis
6.1. Technology & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Technology:
6.2.1. Cell-Free DNA Methylation and Fragmentomics
6.2.2. Next-Generation Sequencing Panels
6.2.3. PCR, Immunohistochemistry and In Situ Hybridization
6.2.4. Proteomic and Multi-Omic Signatures
Chapter 7. Market Segmentation 3: By End User Estimates & Trend Analysis
7.1. End User & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
7.2.1. Hospitals and Cancer Centers
7.2.2. Reference and Specialty Laboratories
7.2.3. Primary Care, Employers and Screening Programs
7.2.4. Pharmaceutical and Biotechnology Companies
Chapter 8. Multi-Cancer Early Detection (MCED) & Companion Diagnostics Market: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. United States
8.1.2. Canada
8.2. Europe
8.2.1. Germany
8.2.2. United Kingdom
8.2.3. France
8.2.4. Italy
8.2.5. Spain
8.2.6. Rest of Europe
8.3. Asia Pacific
8.3.1. China
8.3.2. Japan
8.3.3. India
8.3.4. South Korea
8.3.5. Australia
8.3.6. Southeast Asia
8.3.7. Rest of Asia Pacific
8.4. Latin America
8.4.1. Brazil
8.4.2. Mexico
8.4.3. Rest of Latin America
8.5. Middle East & Africa
8.5.1. GCC Countries
8.5.2. South Africa
8.5.3. Rest of Middle East & Africa
Chapter 9. Competitive Landscape
9.1. Company Market Positioning Analysis
9.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 10. Company Profiles
10.1. GRAIL, Inc.
10.2. Exact Sciences Corporation
10.3. Guardant Health, Inc.
10.4. Roche Holding AG (Foundation Medicine)
10.5. Thermo Fisher Scientific Inc.
10.6. Illumina, Inc.
10.7. Agilent Technologies, Inc.
10.8. QIAGEN N.V.
10.9. Freenome Holdings, Inc.
10.10. Delfi Diagnostics, Inc.
10.11. Harbinger Health, Inc.
10.12. Caris Life Sciences
10.13. Tempus AI, Inc.
10.14. Burning Rock Biotech Limited
10.15. Novigenix SA
圖表清單 List of Tables & Figures
Table 1. Global Multi-Cancer Early Detection (MCED) & Companion Diagnostics Market Revenue Forecast by Test Type, 2026-2035 (US$ Mn)
Figure 1. Global Multi-Cancer Early Detection (MCED) & Companion Diagnostics Market Segmentation and Scope Overview
Table 2. Global Multi-Cancer Early Detection (MCED) & Companion Diagnostics Market Revenue Forecast by Technology, 2026-2035 (US$ Mn)
Figure 2. Global Multi-Cancer Early Detection (MCED) & Companion Diagnostics Market Share by Test Type, 2026 & 2035
Table 3. Global Multi-Cancer Early Detection (MCED) & Companion Diagnostics Market Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 3. Cancer Molecular Diagnostics Continuum from Population Screening to Therapy Selection
Table 4. Global Multi-Cancer Early Detection (MCED) & Companion Diagnostics Market Revenue Forecast by Region, 2026-2035 (US$ Mn)
Figure 4. Multi-Cancer Early Detection Trial Evidence and Reimbursement Pathway Timeline, 2026-2032
Table 5. North America Multi-Cancer Early Detection (MCED) & Companion Diagnostics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific Multi-Cancer Early Detection (MCED) & Companion Diagnostics Growth Opportunity Analysis
Table 6. Europe Multi-Cancer Early Detection (MCED) & Companion Diagnostics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Competitive Positioning of Key Multi-Cancer Early Detection (MCED) & Companion Diagnostics Market Participants
Table 7. Asia Pacific Multi-Cancer Early Detection (MCED) & Companion Diagnostics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Porter's Five Forces Analysis of the Global Multi-Cancer Early Detection (MCED) & Companion Diagnostics Market
Table 8. Strategic Developments of Leading Multi-Cancer Early Detection (MCED) & Companion Diagnostics Market Participants, 2023-2026
Figure 8. Companion Diagnostic Approvals by Biomarker, Format and Therapeutic Class
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們